



Germline variation at 8q24 and prostate cancer risk in men of European ancestry

Marco Matejcic, Edward J Saunders, Tokhir Dadaev, Mark N Brook, Kan Wang, Xin Sheng, Ali Amin Al Olama, Fredrick R Schumacher, Sue A Ingles, Koveela Govindasami, et al.

► To cite this version:

Marco Matejcic, Edward J Saunders, Tokhir Dadaev, Mark N Brook, Kan Wang, et al.. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9 (1), 10.1038/s41467-018-06863-1 . hal-01924689

HAL Id: hal-01924689

<https://hal.sorbonne-universite.fr/hal-01924689>

Submitted on 16 Nov 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ARTICLE

DOI: 10.1038/s41467-018-06863-1

OPEN

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

Marco Matejic, Edward J. Saunders et al.[#]

Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer ($p < 4.28 \times 10^{-15}$), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62–4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification.

Correspondence and requests for materials should be addressed to C.A.H. (email: Christopher.Haiman@med.usc.edu). [#]A full list of authors and their affiliations appears at the end of the paper.

Prostate cancer (PCa) is the most common cancer among men in the US, with 161,360 new cases and 26,730 related deaths estimated in 2017¹. Familial and epidemiological studies have provided evidence of substantial heritability of PCa², and ~170 common risk loci have been identified through genome-wide association studies (GWAS)³. The susceptibility region on chromosome 8q24 has been shown to be a major contributor to PCa risk, with multiple variants clustered in five linkage disequilibrium (LD) blocks spanning ~600 Mb that are independently associated with risk⁴. Many of these association signals reported at 8q24 have been replicated across racial/ethnic populations^{5,6}, pointing to common shared functional variants within 8q24. However, rare ancestry-specific variants have also been detected, which confer larger relative risks of PCa (odds ratios [ORs] >2.0) than common risk variants in the region and signify allelic heterogeneity in the contribution of germline variation at 8q24 to PCa risk across populations⁷.

In the current study, we perform a comprehensive investigation of genetic variation across the 1.4 Mb cancer susceptibility region at 8q24 (127.6–129.0 Mb) in relation to PCa risk. We combine genotyped and imputed data from two large GWAS consortia (PRACTICAL/ELLIPSE OncoArray and iCOGS) including >124,000 individuals of European ancestry to search for novel risk variants, as well as to determine the overall contribution of genetic variation at 8q24 to PCa heritability. Our findings underscore the sizable impact of genetic variation in the 8q24 region in explaining inter-individual differences in PCa risk, with potential clinical utility for genetic risk prediction.

Results

Marginal and conditional association analysis. Genotype data from the Illumina OncoArray and iCOGS array and imputation to 1000 Genomes Project (1KGP) were generated among 71,535 PCa cases and 52,935 controls of European ancestry from 86 case-control studies (see Methods). Of the 5600 genotyped and imputed variants at 8q24 (127.6–129.0 Mb) with minor allele frequency (MAF) >0.1% retained for analysis (see Methods), 1268 (23%) were associated with PCa risk at $p < 5 \times 10^{-8}$ while 2772 (49%) were marginally associated at $p < 0.05$. These 5600 markers capture, at $r^2 > 0.8$, 90% and 97% of all variants at 8q24

(127.6–129.0 Mb) with $MAF \geq 1\%$ and $\geq 5\%$, respectively (based on 1KGP Phase 3 EUR panel). In a forward and backward stepwise selection model on variants marginally associated with PCa risk ($p < 0.05$, $n = 2772$; see Methods), we identified 12 variants with conditional p -values from the Wald test between 2.93×10^{-137} and 4.28×10^{-15} (Table 1). None of the other variants were statistically significant at $p < 5 \times 10^{-8}$ after adjustment for the 12 independent hits (Fig. 1). The 8q24 region is shown in Supplementary Fig. 1. Of these 12 stepwise signals, three had alleles with extreme risk allele frequencies (RAFs) that conveyed large effects (rs77541621, $RAF = 2\%$, $OR = 1.85$, $95\%CI = 1.76\text{--}1.94$; rs183373024, $RAF = 1\%$, $OR = 2.67$, $95\%CI = 2.43\text{--}2.93$; rs190257175, $RAF = 99\%$, $OR = 1.60$, $95\%CI = 1.42\text{--}1.80$). The remaining variants had RAFs between 0.11 and 0.92 and conditional ORs that were more modest and ranged from 1.10 to 1.37 (Table 1). For 8 of the 12 variants, the allele found to be positively associated with PCa risk was the predominant allele (i.e., >50% in frequency). For two variants, rs78511380 and rs190257175, the marginal associations were not genome-wide significant and substantially weaker than those in the conditional model. For rs78511380, the marginal OR was slightly protective ($OR = 0.97$; $p = 0.027$), but reversed direction and was highly statistically significant when conditioning on the other 11 variants ($OR = 1.19$; $p = 3.5 \times 10^{-18}$; Table 1).

Haplotype analysis. The haplotype analysis showed an additive effect of the 12 independent risk variants consistent with that predicted in the single variant test; co-occurrence of the 8q24 risk alleles on the same haplotype does not further increase the risk of PCa (Supplementary Table 1). The unique haplotype carrying the reference allele for rs190257175 (GCTTAT, 0.5% frequency) is also the sole haplotype associated with a reduced risk of PCa, suggesting that having the C allele confers a protective effect. The reference allele for rs78511380 (A, 8% frequency) occurs on a haplotype in block 2 together with the risk alleles for rs190257175, rs72725879 and rs5013678 (haplotype GTTTAA, 8%) which obscures the positive association with the T allele of rs78511380. Thus, the marginal protective effect associated with the risk allele for rs78511380 reflects an increased risk associated with the occurrence on a risk haplotype with other risk alleles (Supplementary Table 1).

Table 1 Marginal and conditional estimates for genetic markers at 8q24 independently associated with prostate cancer risk								
Variant ID ^a	Position ^b	Allele ^c	RAF ^d	LD cluster ^e	Conditional association ^f		Marginal association	
					OR (95%CI) ^g	p-value	OR (95%CI) ^h	p-value
rs1914295	127910317	T/C	0.68	block 1	1.10 (1.08–1.12)	7.30×10^{-25}	1.09 (1.07–1.11)	3.07×10^{-21}
rs1487240	128021752	A/G	0.74	block 1	1.20 (1.17–1.22)	2.77×10^{-66}	1.16 (1.14–1.18)	2.97×10^{-54}
rs77541621	128077146	A/G	0.02	block 2	1.85 (1.76–1.94)	2.93×10^{-137}	1.83 (1.74–1.92)	4.33×10^{-137}
rs190257175	128103466	T/C	0.99	block 2	1.60 (1.42–1.80)	4.28×10^{-15}	1.36 (1.22–1.53)	6.90×10^{-8}
rs72725879	128103969	T/C	0.18	block 2	1.31 (1.28–1.35)	1.26×10^{-83}	1.17 (1.14–1.19)	3.96×10^{-48}
rs5013678	128103979	T/C	0.78	block 2	1.10 (1.08–1.13)	1.58×10^{-19}	1.20 (1.17–1.22)	4.44×10^{-68}
rs183373024	128104117	G/A	0.01	block 2	2.67 (2.43–2.93)	4.89×10^{-95}	3.20 (2.92–3.50)	6.60×10^{-138}
rs78511380	128114146	T/A	0.92	block 2	1.19 (1.14–1.23)	3.48×10^{-18}	0.97 (0.94–1.00)	0.027
rs17464492	128342866	A/G	0.72	block 3	1.16 (1.14–1.18)	3.01×10^{-52}	1.17 (1.15–1.19)	9.05×10^{-61}
rs6983267	128413305	G/T	0.51	block 4	1.18 (1.16–1.20)	5.68×10^{-84}	1.23 (1.21–1.25)	3.15×10^{-135}
rs7812894	128520479	A/T	0.11	block 5	1.37 (1.33–1.40)	1.55×10^{-122}	1.45 (1.41–1.49)	1.20×10^{-181}
rs12549761	128540776	C/G	0.87	block 5	1.21 (1.18–1.24)	1.61×10^{-45}	1.28 (1.25–1.31)	1.38×10^{-78}

^a Variants that remained genome-wide significantly associated with PCa risk ($p < 10^{-8}$) in the final stepwise model

^b Chromosome position based on human genome build 37

^c Risk allele/reference allele


^d Risk allele frequency

^e LD clusters were inferred based on recombination hotspots using Haploview 4.2²⁹ and defined as previously reported by Al Olama et al.⁴

^f Each variant was incorporated in the stepwise model based on the strength of marginal association from the meta-analysis of OncoArray and iCOGS data

^g Per-allele odds ratio and 95% confidence interval adjusted for country, 7(OncoArray)/8(iCOGS) principal components and all other variants in the table

^h Per-allele odds ratio and 95% confidence interval adjusted for country and 7(OncoArray)/8(iCOGS) principal components



Correlation with known risk loci. The 12 risk variants spanned across the five LD blocks previously reported to harbor risk variants for PCa at 8q24⁴, with block 2 harboring six signals, blocks 1 and 5 two signals each, and blocks 3 and 4 only one (Supplementary Fig. 2). Except for a weak correlation between

rs72725879 and rs78511380 in block 2 ($r^2 = 0.28$), the risk variants were uncorrelated with each other ($r^2 \leq 0.09$; Supplementary Data 1), which corroborates their independent association with PCa risk. Eight of the variants (rs1487240, rs77541621, rs72725879, rs5013678, rs183373024, rs17464492, rs6983267,

Fig. 1 LocusExplorer plots of the 12 variants at 8q24 significantly associated with PCa risk. ‘Marginal’ and ‘Conditional’ Manhattan plot panels show marginal and conditional association results, respectively. Variant positions (x-axis) and $-\log_{10} p$ -values from the Wald test (y-axis) are shown, with the red line indicating the threshold for genome-wide significant association with PCa risk ($p \leq 5 \times 10^{-8}$) and blue peaks local estimates of recombination rates. The position of the 12 independent variants is labeled in each plot. Clusters of correlated variants for each independent signal are distinguished using different colors and also depicted on the ‘LD r^2 Hits’ track. Stronger shading indicates greater correlation with the lead variant, with variants not correlated at $r^2 \geq 0.2$ with any lead variant uncolored. Pairwise correlations are based on the European ancestry (EUR) panel from the 1000 Genomes Project (1KGP) Phase 3. The relative position of RefSeq genes and biological annotations are shown in the ‘Genes’ and ‘Biofeatures’ panels, respectively. Genes on the positive strand are denoted in green and those on the negative strand in purple. Annotations displayed are: histone modifications in ENCODE tier 1 cell lines (Histone track), the positions of any variants that were eQTLs with prostate tumor expression in TCGA prostate adenocarcinoma samples and the respective genes for which expression is altered (eQTL track), chromatin state categorizations in the PrEC cell-line by ChromHMM (ChromHMM track), the position of conserved element peaks (Conserved track) and the position of DNaseI hypersensitivity site peaks in ENCODE prostate cell-lines (DNaseI track). The data displayed in this plot may be explored interactively through the LocusExplorer application (<http://www.oncogenetics.icr.ac.uk/8q24/>)

Table 2 Relative risk of PCa for polygenic risk score (PRS) groups				
Risk category percentile ^a	No. of individuals		Risk estimates for PRS groups	
	Controls	Cases	OR (95% CI) ^b	p-value
≤1%	530	339	0.52 (0.45–0.59)	2.11×10^{-20}
1%–10%	4771	3636	0.62 (0.59–0.65)	6.26×10^{-90}
10%–25%	7936	7359	0.75 (0.72–0.78)	3.62×10^{-54}
25%–75%	26,464	32,743	1.00 (Ref)	
75%–90%	7940	13,431	1.37 (1.32–1.41)	6.55×10^{-77}
90%–99%	4766	11,451	1.93 (1.86–2.01)	4.13×10^{-249}
>99%	528	2576	3.99 (3.62–4.40)	5.64×10^{-172}

Note: PRS were calculated for variants from the final stepwise model with allele dosage from OncoArray and iCOGS weighted by the per-allele conditionally adjusted odds ratios from the meta-analysis
^aRisk category groups were based on the percentile distribution of risk alleles in overall controls
^bEstimated effect of each PRS group relative to the interquartile range (25–75%) in OncoArray and iCOGS datasets separately, and then meta-analyzed across the two studies; odds ratios were adjusted for country and 7(OncoArray)/8(iCOGS) principal components

Table 3 Proportion of familial relative risk (FRR) and heritability (h_g^2) of PCa explained by known risk variants					
Source	No. of variants	Proportion of FRR (95%CI)	% of total FRR	h_g^2 (SE)	% of total h_g^2
8q24 ^a	12	9.42 (8.22–10.88)	25.4	0.027 (0.011)	22.2
HOXB13 ^b	1	1.91 (1.20–2.85)	5.2	0.004 (0.005)	3.0
All other variants ^{b,c}	162	25.77 (22.94–29.36)	69.5	0.092 (0.010)	74.9
Total	175	37.08 (32.89–42.49)	100	0.118 (0.012)	100

^aConditional estimates were derived by fitting a single model with all variants from OncoArray data
^bRisk estimates and allele frequencies for regions with a single variant are from a meta-analysis of OncoArray, iCOGS and 6 additional GWAS³
^cRisk variants included from fine-mapping of PCa susceptibility loci in European ancestry populations¹¹

rs7812894) have been previously reported either directly (Supplementary Table 2) or are correlated ($r^2 \geq 0.42$) with known markers of PCa risk from studies in populations of European, African or Asian ancestry (Supplementary Data 1)^{4,7–10}. The marginal estimates for previously published PCa risk variants at 8q24 in the current study are shown in Supplementary Table 2. The variant rs1914295 in block 1 is only weakly correlated with the previously reported risk variants rs12543663 and rs10086908 ($r^2 = 0.17$ and 0.14 , respectively), while rs7851380 is modestly correlated with the previously reported risk variant rs1016343 ($r^2 = 0.28$). The remaining two variants, rs190257175 and rs12549761, are not correlated ($r^2 < 0.027$) with any known PCa risk marker.

Polygenic risk score and familial relative risk. To estimate the cumulative effect of germline variation at 8q24 on PCa risk, a polygenic risk score (PRS) was calculated for the 12 independent risk alleles from the final model based on allele dosages weighted by the per-allele conditionally adjusted ORs (see Methods). Compared to the men at ‘average risk’ (i.e., the 25th–75th PRS range among controls), men in the top 10% of the PRS

distribution had a 1.93-fold relative risk (95%CI = 1.86–2.01) (Table 2), with the risk being 3.99-fold higher (95%CI = 3.62–4.40) for men in the top 1%. Risk estimates by PRS category were not modified by family history (FamHist-yes: OR = 4.24, 95%CI = 2.85–6.31; FamHist-no: OR = 3.38, 95%CI = 2.88–3.97). To quantify the impact of germline variation at 8q24, we also estimated the proportion of familial relative risk (FRR) and heritability of PCa contributed by 8q24 and compared this to the proportions explained by all known PCa risk variants including 8q24 (see Methods). The 175 established PCa susceptibility loci identified to date^{3,11} are estimated to explain 37.08% (95%CI = 32.89–42.49) of the FRR of PCa, while the 12 independent signals at 8q24 alone capture 9.42% (95%CI = 8.22–10.88), which is 25.4% of the total FRR explained by known genetic risk factors for PCa (Table 3). This is similar to the proportion of heritability explained by 8q24 variants (22.2%) compared to the total explained heritability by the known risk variants (0.118). In comparison, the next highest contribution of an individual susceptibility region to the FRR of PCa is the *TERT* region at chromosome 5p15, where 5 independent signals contributed 2.63% (95%CI = 2.34–3.00). No other individual GWAS

locus has been established as explaining >2% of the FRR, including the low frequency, non-synonymous, moderate penetrance *HOXB13* variant (rs138213197) at chromosome 17q21 that is estimated to explain only 1.91% (95%CI = 1.20–2.85) of the FRR¹¹.

JAM analysis. We explored our data with a second fine-mapping approach, JAM (Joint Analysis of Marginal summary statistics)¹², which uses GWAS summary statistics to identify credible sets of variants that define the independent association signals in susceptibility regions (see Methods). The 95% credible set for the JAM analysis confirmed all of the independent signals from stepwise analysis except rs190257175, for which evidence for an association was weak (variant-specific Bayes factor (BF) = 1.17). There were 50 total variants included in the 95% credible set, and 174 after including variants in high LD ($r^2 > 0.9$) with those in the credible set (Supplementary Data 2).

Discussion

In this large study of germline genetic variation across the 8q24 region, we identified 12 independent association signals among men of European ancestry, with three of the risk variants (rs1914295, rs190257175, and rs12549761) being weakly correlated ($r^2 \leq 0.17$) with known PCa risk markers. The combination of these 12 independent signals at 8q24 capture approximately one quarter of the total PCa FRR explained by known genetic risk factors, which is substantially greater than any other known PCa risk locus.

The 8q24 region is the major susceptibility region for PCa; however, the underlying biological mechanism(s) through which germline variation in this region influences PCa risk remains uncertain. For each of the 12 risk variants at 8q24, the 95% credible set defined noteworthy (i.e., putative functional) variants based on summary statistics while accounting for LD. To inform biological functionality, we overlaid epigenetic functional annotation using publicly available datasets (see Methods) with the location of the 12 independent signals (and corresponding 174 variants within their 95% credible sets; Supplementary Data 3). Of the 12 independent lead variants, 6 are situated within putative transcriptional enhancers in prostate cell-lines; either through intersection with H3K27AC (rs72725879, rs5013678, rs78511380, rs6983267 and rs7812894) or through a ChromHMM enhancer annotation (rs17464492, rs6983267, rs7812894). Eight of the 12 stepwise hits (rs77541621, rs190257175, rs5013678, rs183373024, rs78511380, rs17464492, rs6983267, rs7812894) also intersect transcription factor binding site peaks from multiple ChIP-seq datasets representing the AR, ERG, FOXA1, GABPA, GATA2, HOXB13, and NKX3.1 transcription factors, with all 8 intersecting a FOXA1 mark and half an AR binding site. These variants may therefore exert their effect through regulation of enhancer activity and long-range expression of genes important for cancer tumorigenesis and/or progression¹³. The variant rs6983267 has also been shown to act in an allele-specific manner to regulate prostate enhancer activity and expression of the proto-oncogene *MYC* in vitro and in vivo^{14,15}. However, despite the close proximity to the *MYC* locus, no direct association has been detected between 8q24 risk alleles and *MYC* expression in normal and tumor human prostate tissues¹⁶. The rare variant with the largest effect on risk, rs183373024, shows high evidence of functionality based on overlap with multiple DNaseI and transcription factor binding site peaks (for AR, FOXA1, HOXB13, and NKX3.1), which supports previous findings of an allele-dependent effect of this variant on the disruption of a FOXA1 binding motif¹⁷. Seven independent signals (rs1914295, rs1487240, rs77541621, rs72725879, rs5013678, rs183373024,

rs78511380) and variants correlated at $r^2 > 0.9$ with these signals (Supplementary Data 2) are located within or near a number of prostate cancer-associated long noncoding RNAs (lncRNAs), including *PRNCRI*, *PCATI*, and *CCAT2*, previously reported to be upregulated in human PCa cells¹⁸ and tissues^{19,20}. Based on eQTL annotations in prostate adenocarcinoma cells, the independent signal rs1914295 and three correlated variants ($r^2 > 0.9$; Supplementary Data 2) are associated with overexpression of *FAM84B*, a gene previously associated with progression and poor prognosis of PCa in animal studies²¹. Variants correlated at $r^2 > 0.9$ with rs7812894 ($n = 9$; Supplemental Table 4) are eQTLs for *POU5F1B*, a gene overexpressed in cancer cell lines and cancer tissues^{22,23}, although its role in PCa development is unknown. Whilst we have successfully refined the 8q24 region and identified a subset of variants with putative biological function within our credible set, multi-ethnic comparisons may help refine the association signals even further and precisely identify the functional alleles and biological mechanisms that modify PCa risk.

Whereas the individual associations of the 8q24 variants with PCa risk are relatively modest (ORs < 2.0, except for rs183373024), their cumulative effects are substantial, with risk being 4-fold higher for men in the top 1% of the 8q24-only PRS. The contribution to the overall FRR of PCa is substantially greater for the 8q24 region (9.42%) than for any other known GWAS locus, including the moderate penetrance non-synonymous variant in *HOXB13* (1.91%). The ability of these markers to explain ~25.4% of what can be currently explained by all known PCa risk variants is a clear indication of the important contribution of germline variation at 8q24 on PCa risk. Our study was predominantly powered to analyze variants with MAF > 1% as the imputed variants with MAF = 0.1–1% were most likely to fail quality control (QC); however, the high density of genotyped markers and haplotypes at 8q24 in the OncoArray and iCOGS studies provided a robust backbone for imputation and increased the chances to impute lower MAF variants with high imputation quality score. Understanding of the biology of these variants and the underlying genetic basis of PCa could provide new insights into the identification of reliable risk-prediction biomarkers for PCa, as well as enable the development of effective strategies for targeted screening and prevention.

Methods

Study subjects, genotyping, and quality control. We combined genotype data from the PRACTICAL/ELLIPSE OncoArray and iCOGS consortia^{3,24}, which included 143,699 men of European ancestry from 86 case-control studies largely based in either the US or Europe. In each study, cases primarily included men with incident PCa while controls were men without a prior diagnosis of the disease.

Both of the OncoArray and iCOGS custom arrays were designed to provide high coverage of common alleles (minor allele frequency [MAF] > 5%) across 8q24 (127.6–129.0 Mb) based on the 1000 Genomes Project (1KGP) Phase 3 for OncoArray, and the European ancestry (EUR) panel from HapMap Phase 2 for iCOGS. A total of 57,580 PCa cases and 37,927 controls of European ancestry were genotyped with the Illumina OncoArray, and 24,198 PCa cases and 23,994 controls of European ancestry were genotyped with the Illumina iCOGS array. For both studies, sample exclusion criteria included duplicate samples, first-degree relatives, samples with a call rate < 95% or with extreme heterozygosity ($p < 10^{-6}$), and samples with an estimated proportion of European ancestry < 0.8^{3,24}. In total, genotype data for 53,449 PCa cases and 36,224 controls from OncoArray and 18,086 PCa cases and 16,711 controls from iCOGS were included in the analysis. Genetic variants with call rates < 0.95, deviation from Hardy-Weinberg equilibrium ($p < 10^{-7}$ in controls), and genotype discrepancy in > 2% of duplicate samples were excluded. Of the final 498,417 genotyped variants on the OncoArray and 201,598 on the iCOGS array that passed QC, 1581 and 1737 within the 8q24 region, respectively, were retained for imputation.

All studies complied with all relevant ethical regulations and were approved by the institutional review boards at each of the participating institutions. Informed consent was obtained from all study participants. Additional details of each study are provided in the Supplementary Note 1.

Imputation analysis. Imputation of both OncoArray and iCOGS genotype data was performed using SHAPEIT²⁵ and IMPUTEv2²⁶ to the October 2014 (Phase 3)

release of the 1KGP reference panel. A total of 10,136 variants from OncoArray and 10,360 variants from iCOGS with MAF > 0.1% were imputed across the risk region at 8q24 (127.6–129.0 Mb). Variants with an imputation quality score > 0.8 were retained for a total of 5600 overlapping variants between the two datasets.

Statistical analysis. Unconditional logistic regression was used to estimate per-allele odds ratios (ORs) and 95% confidence intervals (CIs) for the association between genetic variants (single nucleotide polymorphisms and insertion/deletion polymorphisms) and PCA risk adjusting for country and principal components (7 for OncoArray and 8 for iCOGS). Allele dosage effects were tested through a 1-degree of freedom two-tailed Wald trend test. The marginal risk estimates for the 5600 variants at 8q24 that passed QC were combined by a fixed effect meta-analysis with inverse variance weighting using METAL²⁷. A modified forward and backward stepwise model selection with inclusion and exclusion criteria of $p \leq 5 \times 10^{-8}$ was performed on variants marginally associated with PCA risk from the meta results ($p < 0.05$, $n = 2772$). At each step, the effect estimates for the candidate variants from both studies (OncoArray and iCOGS) were meta-analyzed and each variant was incorporated into the model based on the strength of association. All remaining variants were included one-at-a-time into the logistic regression model conditioning on those already incorporated in the model. We applied a conservative threshold for independent associations, with variants kept in the model if their meta p -value from the Wald test was genome-wide significant at $p \leq 5 \times 10^{-8}$ after adjustment for the other variants in the model. Correlations between variants in the final model and previously published PCA risk variants at 8q24 were estimated using the 1KGP Phase 3 EUR panel (Supplementary Data 1).

Haplotype analysis. Haplotypes were estimated in the Oncoarray data only using variants from the final stepwise model selection ($n = 12$) and the EM algorithm²⁸ within LD block regions inferred based on recombination hotspots using Haploview 4.2 (Broad Institute, Cambridge, MA, USA)²⁹. Only haplotypes with an estimated frequency $\geq 0.5\%$ were tested.

Polygenic risk score and familial relative risk. An 8q24-only polygenic risk score (PRS) was calculated for variants from the final model ($n = 12$) with allele dosage from OncoArray and iCOGS weighted by the per-allele conditionally adjusted ORs from the meta-analysis. Categorization of the PRS was based on the percentile distribution in controls, and the risk for each category was estimated relative to the interquartile range (25–75%) in OncoArray and iCOGS separately, and then meta-analyzed across the two studies. We estimated the contribution of 8q24 variants to the familial (first-degree) relative risk (FRR) of PCA (FRR = 2.5)³⁰ under a multiplicative model, and compared this to the FRR explained by all known PCA risk variants including 8q24 (Supplementary Data 4). We also estimated heritability of PCA using the LMM approach as implemented in GCTA³¹. For regions which have been fine-mapped using the OncoArray meta-analysis data, we used the updated representative lead variants, otherwise the originally reported variant was included provided that it had replicated at genome-wide significance in the meta-analysis; this identified a total of 175 independently associated PCA variants for the FRR and heritability calculations^{3,11}. For these analyses, we used conditional estimates from fitting a single model with all variants in the OncoArray dataset for regions with multiple variants and the overall marginal meta-analysis results from Schumacher et al.³ for regions with a single variant. To correct for potential bias in effect estimation of newly discovered variants, we implemented a Bayesian version of the weighted correction³², which incorporates the uncertainty in the effect estimate into the final estimates of the bias-corrected ORs, 95% CIs and the corresponding calculations of percent FRR explained.

JAM analysis. To confirm the stepwise results and identify candidate variants for potential functional follow-up, we used a second fine-mapping approach, JAM (Joint Analysis of Marginal summary statistics)¹². JAM is a multivariate Bayesian variable selection framework that uses GWAS summary statistics to identify the most likely number of independent associations within a locus and define credible sets of variants driving those associations. JAM was applied to summary statistics from the meta-analysis results using LD estimated from imputed individual level data from 20,000 cases and 20,000 controls randomly selected from the OncoArray sub-study. LD pruning was performed using Priority Pruner (<http://prioritypruner.sourceforge.net/>) on the 2772 marginally associated variants at $r^2 = 0.9$, resulting in 825 tag variants analyzed in four independent JAM runs with varying starting seeds. Credible sets were determined as the tag variants that were selected in the top models that summed to a specific cumulative posterior probability in all four of the independent JAM runs, plus their designated high LD proxy variants from the pruning step.

Functional annotation. Variants in the 95% credible set ($n = 50$) plus variants correlated at $r^2 > 0.9$ with those in the credible set ($n = 174$) were annotated for putative evidence of biological functionality using publicly available datasets as described by Dadaev et al.¹¹. Briefly, variants were annotated for proximity to gene (GENCODEv19), miRNA transcripts (miRBase release 20), evolutionary constraint (according to GERP++, SiPhy and PhastCons algorithms), likelihood of

pathogenicity (CADDv1.3) and overlap with prospective regulatory elements in prostate-specific datasets (DNaseI hypersensitivity sites, H3K27Ac, H3K27me3 and H3K4me3 histone modifications, and for AR, CTCF, ERG, FOXA1, GABPA, GATA2, HOXB13, and NKX3.1 transcription factor binding sites) in a mixture of LNCaP, PC-3, PREC, RWPE1, and VCaP cell lines and human prostate tumor tissues downloaded from the Cistrome Data Browser (<http://cistrome.org/db/>). The chromatin state in which each variant resides was assessed using ChromHMM annotations from two prostate cell lines (PREC and PC3). Cis-gene regulation was evaluated using 359 prostate adenoma cases from The Cancer Genome Atlas (TCGA PRAD; <https://gdc-portal.nci.nih.gov>) that passed QC¹¹. The eQTL analysis was performed using FastQTL with 1000 permutations for each gene within a 1Mb window. We then used the method by Nica et al.³³ that integrates eQTLs and GWAS results in order to reveal the subset of association signals that are due to cis eQTLs. For each significant eQTL, we added the candidate variant to the linear regression model to assess if the inclusion better explains the change in expression of the gene. We retrieved the p -value of the model, assigning p -value of 1 if the eQTL and variant are the same. Then we ranked the p -values in descending order for each eQTL, and finally calculated the colocalization score for each pair of eQTL and variants. In general, if an eQTL and candidate variant represent the same signal, this will be reflected by the variant having a high p -value, a low rank and consequently a high colocalization score.

Data availability

The authors declare that data supporting the findings of this study are available within the paper [and in the supplementary information files]. However, some of the data used to generate the results of this study are available from the first author and the PRAC-TICAL Consortium upon request.

Received: 7 February 2018 Accepted: 1 October 2018

Published online: 05 November 2018

References

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. *CA Cancer J. Clin.* **67**, 7–30 (2017).
2. Hjelmborg, J. B. et al. The heritability of prostate cancer in the Nordic Twin Study of Cancer. *Cancer Epidemiol. Prev. Biomark.* **23**, 2303–2310 (2014).
3. Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat. Genet.* **50**, 928–936 (2018).
4. Al Olama, A. A. et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. *Nat. Genet.* **41**, 1058–1060 (2009).
5. Haiman, C. A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat. Genet.* **39**, 638–644 (2007).
6. Han, Y. et al. Generalizability of established prostate cancer risk variants in men of African ancestry. *Int. J. Cancer* **136**, 1210–1217 (2015).
7. Gudmundsson, J. et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. *Nat. Genet.* **44**, 1326–1329 (2012).
8. Han, Y. et al. Prostate cancer susceptibility in men of African ancestry at 8q24. *J. Natl Cancer Inst.* **108**, djv431 (2016).
9. Hoffmann, T. J. et al. A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. *Cancer Discov.* **5**, 878–891 (2015).
10. Conti, D. V. et al. Two novel susceptibility loci for prostate cancer in men of African ancestry. *J. Natl Cancer Inst.* **109**, djx084 (2017).
11. Dadaev, T. et al. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nat. Commun.* **9**, 2256 (2018).
12. Newcombe, P. J., Conti, D. V. & Richardson, S. JAM: a scalable Bayesian framework for joint analysis of marginal SNP effects. *Genet. Epidemiol.* **40**, 188–201 (2016).
13. Jia, L. et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. *PLoS Genet.* **5**, e1000597 (2009).
14. Pomerantz, M. M. et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. *Nat. Genet.* **41**, 882–884 (2009).
15. Wasserman, N. F., Aneas, I. & Nobrega, M. A. An 8q24 gene desert variant associated with prostate cancer risk confers differential *in vivo* activity to a MYC enhancer. *Genome Res.* **20**, 1191–1197 (2010).
16. Pomerantz, M. M. et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. *Cancer Res.* **69**, 5568–5574 (2009).
17. Hazelett, D. J., Coetzee, S. G. & Coetzee, G. A. A rare variant, which destroys a FoxA1 site at 8q24, is associated with prostate cancer risk. *Cell Cycle Georget. Tex.* **12**, 379–380 (2013).

18. Chung, S. et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. *Cancer Sci.* **102**, 245–252 (2011).
19. Prensner, J. R. et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. *Nat. Biotechnol.* **29**, 742–749 (2011).
20. Zheng, J. et al. The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition. *Biochem. Biophys. Res. Commun.* **480**, 508–514 (2016).
21. Wong, N. et al. Upregulation of FAM84B during prostate cancer progression. *Oncotarget* **8**, 19218–19235 (2017).
22. Suo, G. et al. Oct4 pseudogenes are transcribed in cancers. *Biochem. Biophys. Res. Commun.* **337**, 1047–1051 (2005).
23. Hayashi, H. et al. The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. *Oncogene* **34**, 199–208 (2015).
24. Eeles, R. A. et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nat. Genet.* **45**, 385–391 (2013).
25. Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for thousands of genomes. *Nat. Methods* **9**, 179–181 (2011).
26. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* **5**, e1000529 (2009).
27. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinforma. Oxf. Engl.* **26**, 2190–2191 (2010).
28. Excoffier, L. & Slatkin, M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. *Mol. Biol. Evol.* **12**, 921–927 (1995).
29. Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. *Bioinforma. Oxf. Engl.* **21**, 263–265 (2005).
30. Johns, L. E. & Houlston, R. S. A systematic review and meta-analysis of familial prostate cancer risk. *BJU Int.* **91**, 789–794 (2003).
31. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
32. Zhong, H. & Prentice, R. L. Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies. *Biostat. Oxf. Engl.* **9**, 621–634 (2008).
33. Nica, A. C. et al. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. *PLoS Genet.* **6**, e1000895 (2010).

Acknowledgements

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). The PRACTICAL consortium (<http://practical.icr.ac.uk/>) was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). We

wish to thank all GWAS study groups contributing to the data set from which this study was conducted: OncoArray; iCOGS; The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; and The GAME-ON/ELLIPSE Consortium. Detailed acknowledgements and funding information for all GWAS study groups and from all the individual studies involved in the PRACTICAL Consortium are included in Supplementary Note 1. We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

Author contributions

M.M. and E.J.S. contributed equally to this work. R.A.E., Z.K.-J., D.V.C., and C.A.H. jointly supervised this work. T.D. contributed with JAM analysis. M.N.B. contributed with FRR analysis. K.W. contributed with forward and backward stepwise selection. X.S. contributed with coverage analysis. A.A.A.O., F.R.S., S.A.I., K.G., S.B., S.I.B., D.A., S.K., K.M., V.L.S., S.M.G., C.M.T., J.B., J.C., H.G., N.P., J.S., A.W., C.W., L.Mu., P.K., G.C.-T., K.D.S., L.Ma., E.M.G., S.S.S., D.E.N., F.C.H., J.L.D., R.C.T., R.J.H., B.R., Y.-J.L., G.G.G., A.S.K., A.V., J.T.B., M.K., K.L.P., J.Y.P., J.L.S., C.C., B.G.N., H.B., C.M., J.K., M.R.T., S.L.N., K.D.R., A.R., L.F.N., D.L., R.K., N.U., F.C., P.A.T., M.G.D., M.J.R., F.M., K.-T.K., L.A.C.-A., H.P., S.N.T., D.J.S., The PRACTICAL Consortium, F.W., S.J.C., and D.F.E. were involved in sample and data collection.

Additional information

Supplementary Information accompanies this paper at <https://doi.org/10.1038/s41467-018-06863-1>.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018

Marco Matejčić¹, Edward J. Saunders², Tokhir Dadaev², Mark N. Brook², Kan Wang¹, Xin Sheng¹, Ali Amin Al Olama^{3,4}, Fredrick R. Schumacher^{5,6}, Sue A. Ingles¹, Koveela Govindasami², Sara Benlloch^{2,3}, Sonja I. Berndt⁷, Demetrius Albanes⁷, Stella Koutros⁷, Kenneth Muir^{8,9}, Victoria L. Stevens¹⁰, Susan M. Gapstur¹⁰, Catherine M. Tangen¹¹, Jyotsna Batra^{12,13}, Judith Clements^{12,13}, Henrik Gronberg¹⁴, Nora Pashayan^{15,16}, Johanna Schleutker^{17,18,19}, Alicja Wolk²⁰, Catharine West²¹, Lorelei Mucci²², Peter Kraft²³, Géraldine Cancel-Tassin^{24,25}, Karina D. Sorensen^{26,27}, Lovise Maehle²⁸, Eli M. Grindedal²⁸, Sara S. Strom²⁹, David E. Neal^{30,31}, Freddie C. Hamdy³², Jenny L. Donovan³³, Ruth C. Travis³⁴, Robert J. Hamilton³⁵, Barry Rosenstein^{36,37}, Yong-Jie Lu³⁸, Graham G. Giles^{39,40}, Adam S. Kibel⁴¹, Ana Vega⁴², Jeanette T. Bensen⁴³, Manolis Kogevinas^{44,45,46,47}, Kathryn L. Penney⁴⁸, Jong Y. Park⁴⁹, Janet L. Stanford^{50,51}, Cezary Cybulski⁵², Børge G. Nordestgaard^{53,54}, Hermann Brenner^{55,56,57}, Christiane Maier⁵⁸, Jeri Kim⁵⁹,

Manuel R. Teixeira^{60,61}, Susan L. Neuhausen⁶², Kim De Ruyck⁶³, Azad Razack⁶⁴, Lisa F. Newcomb^{50,65}, Davor Lessel⁶⁶, Radka Kaneva⁶⁷, Nawaid Usmani^{68,69}, Frank Claessens⁷⁰, Paul A. Townsend⁷¹, Manuela G. Dominguez^{72,73}, Monique J. Roobol⁷⁴, Florence Menegaux⁷⁵, Kay-Tee Khaw⁷⁶, Lisa A. Cannon-Albright^{77,78}, Hardev Pandha⁷⁹, Stephen N. Thibodeau⁸⁰, Daniel J. Schaid⁸¹, The PRACTICAL Consortium, Fredrik Wiklund¹⁴, Stephen J. Chanock⁷, Douglas F. Easton^{3,15}, Rosalind A. Eeles^{2,82}, Zsafia Kote-Jarai², David V. Conti¹ & Christopher A. Haiman¹

¹Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA. ²The Institute of Cancer Research, London SW7 3RP, UK. ³Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge CB1 8RN, UK. ⁴Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK. ⁵Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106-7219, USA. ⁶Seidman Cancer Center, University Hospitals, Cleveland, OH 44106, USA. ⁷Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA. ⁸Institute of Population Health, University of Manchester, Manchester M13 9PL, UK. ⁹Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK. ¹⁰Epidemiology Research Program, American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA. ¹¹SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. ¹²Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, QLD 4059, Australia. ¹³Translational Research Institute, Brisbane, QLD 4102, Australia. ¹⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden. ¹⁵Centre for Cancer Genetic Epidemiology, Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge CB1 8RN, UK. ¹⁶Department of Applied Health Research, University College London, London WC1E 7HB, UK. ¹⁷Department of Medical Biochemistry and Genetics, Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland. ¹⁸Tyks Microbiology and Genetics, Department of Medical Genetics, Turku University Hospital, 20521 Turku, Finland. ¹⁹BioMediTech, University of Tampere, 33520 Tampere, Finland. ²⁰Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden. ²¹Division of Cancer Sciences, Manchester Academic Health Science Centre, Radiotherapy Related Research, Manchester NIHR Biomedical Research Centre, The Christie Hospital NHS Foundation Trust, University of Manchester, Manchester M13 9PL, UK. ²²Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. ²³Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. ²⁴GRC N°5 ONCOTYPE-URO, UPMC Univ Paris 06, Tenon Hospital, F-75020 Paris, France. ²⁵CeRePP, Tenon Hospital, F-75020 Paris, France. ²⁶Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. ²⁷Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark. ²⁸Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway. ²⁹Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ³⁰Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 0QQ, UK. ³¹Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK. ³²Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 2JD, UK. ³³School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK. ³⁴Cancer Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK. ³⁵Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. ³⁶Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ³⁷Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA. ³⁸Centre for Molecular Oncology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK. ³⁹Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, VIC 3004, Australia. ⁴⁰Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC 3010, Australia. ⁴¹Division of Urologic Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA. ⁴²Fundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica, CIBERER, IDIS, 15706 Santiago de Compostela, Spain. ⁴³Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Columbia, SC 29208, USA. ⁴⁴Centre for Research in Environmental Epidemiology (CREAL), Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain. ⁴⁵CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain. ⁴⁶IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain. ⁴⁷Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain. ⁴⁸Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02184, USA. ⁴⁹Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA. ⁵⁰Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. ⁵¹Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA 98195, USA. ⁵²International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-115 Szczecin, Poland. ⁵³Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark. ⁵⁴Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2200 Copenhagen, Denmark. ⁵⁵Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany. ⁵⁶German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany. ⁵⁷Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany. ⁵⁸Institute for Human Genetics, University Hospital Ulm, 89075 Ulm, Germany. ⁵⁹Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ⁶⁰Department of Genetics, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. ⁶¹Biomedical Sciences Institute (ICBAS), University of Porto, 4050-313 Porto, Portugal. ⁶²Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA. ⁶³Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, B-9000 Gent, Belgium. ⁶⁴Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. ⁶⁵Department of Urology, University of Washington, Seattle, WA 98195, USA. ⁶⁶Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany. ⁶⁷Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, 1431 Sofia, Bulgaria. ⁶⁸Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada. ⁶⁹Division of Radiation Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada. ⁷⁰Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE-3000 Leuven, Belgium. ⁷¹Manchester Cancer Research Centre, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Health Innovation Manchester, University of Manchester, Manchester M13 9WL, UK. ⁷²Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS,

15706 Santiago de Compostela, Spain. ⁷³Moore's Cancer Center, University of California San Diego, La Jolla, CA 92037, USA. ⁷⁴Department of Urology, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands. ⁷⁵Cancer and Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, 94807 Villejuif Cédex, France. ⁷⁶Clinical Gerontology Unit, University of Cambridge, Cambridge CB2 2QQ, UK. ⁷⁷Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA. ⁷⁸George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA. ⁷⁹The University of Surrey, Guildford, Surrey GU2 7XH, UK. ⁸⁰Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA. ⁸¹Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA. ⁸²Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK. These authors contributed equally: Marco Matejic, Edward J. Saunders. These authors jointly supervised this work: Rosalind A. Eeles, Zsolt Kote-Jarai, David V. Conti, Christopher A. Haiman. A full list of consortium members appears at the end of the paper.

The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium

Brian E. Henderson¹, Mariana C. Stern¹, Alison Thwaites², Michelle Guy², Ian Whitmore², Angela Morgan², Cyril Fisher², Steve Hazel², Naomi Livni², Margaret Cook³, Laura Fachal^{3,42}, Stephanie Weinstein⁷, Laura E. Beane Freeman⁷, Robert N. Hoover⁷, Mitchell J. Machiela⁷, Artitaya Lophatananon^{8,9}, Brian D. Carter¹⁰, Phyllis Goodman¹¹, Leire Moya^{12,13}, Srilakshmi Srinivasan^{12,13}, Mary-Anne Kedda^{12,13}, Trina Yeadon^{12,13}, Allison Eckert^{12,13}, Martin Eklund¹⁴, Carin Cavalli-Bjorkman¹⁴, Alison M. Dunning¹⁵, Csilla Sipeky¹⁷, Niclas Hakansson²⁰, Rebecca Elliott²¹, Hardeep Ranu²², Edward Giovannucci²², Constance Turman²³, David J. Hunter²³, Olivier Cussenot^{24,25}, Torben Falck Orntoft^{26,27}, Athene Lane³³, Sarah J. Lewis³³, Michael Davis³³, Tim J. Key³⁴, Paul Brown³⁵, Girish S. Kulkarni³⁵, Alexandre R. Zlotta³⁵, Neil E. Fleshner³⁵, Antonio Finelli³⁵, Xueying Mao³⁸, Jacek Marzec³⁸, Robert J. MacInnis^{39,40}, Roger Milne^{39,40}, John L. Hopper⁴⁰, Miguel Aguado⁴², Mariona Bustamante⁴⁴, Gemma Castaño-Vinyals^{44,45,46,47}, Esther Gracia-Lavedan^{44,45,46,47}, Lluís Cecchini⁴⁶, Meir Stampfer⁴⁸, Jing Ma⁴⁸, Thomas A. Sellers⁴⁹, Milan S. Geybels⁴⁹, Hyun Park⁴⁹, Babu Zachariah⁴⁹, Suzanne Kolb⁵⁰, Dominika Wokolorczyk⁵², Jan Lubinski⁵², Wojciech Kluzniak⁵², Sune F. Nielsen^{53,54}, Maren Weisher⁵⁴, Katarina Cuk⁵⁵, Walther Vogel⁵⁸, Manuel Luedeke⁵⁸, Christopher J. Logothetis⁵⁹, Paula Paulo⁶⁰, Marta Cardoso⁶⁰, Sofia Maia⁶⁰, Maria P. Silva⁶⁰, Linda Steele⁶², Yuan Chun Ding⁶², Gert De Meerleer⁶³, Sofie De Langhe⁶³, Hubert Thierens⁶³, Jasmine Lim⁶⁴, Meng H. Tan⁶⁴, Aik T. Ong⁶⁴, Daniel W. Lin^{50,65}, Darina Kachakova⁶⁷, Atanaska Mitkova⁶⁷, Vanio Mitev⁶⁷, Matthew Parliament^{68,69}, Guido Jenster⁷⁴, Christopher Bangma⁷⁴, F.H. Schroder⁷⁴, Thérèse Truong⁷⁵, Yves Akoli Koudou⁷⁵, Agnieszka Michael⁷⁹, Andrzej Kierzek⁷⁹, Ami Karlsson⁷⁹, Michael Broms⁷⁹, Huihai Wu⁷⁹, Claire Aukim-Hastie⁷⁹, Lori Tillmans⁸⁰, Shaun Riska⁸⁰, Shannon K. McDonnell⁸¹, David Dearnaley^{2,82}, Amanda Spurdle⁸³, Robert Gardiner^{84,85}, Vanessa Hayes⁸⁶, Lisa Butler⁸⁷, Renea Taylor⁸⁸, Melissa Papargiris⁸⁸, Pamela Saunders⁸⁹, Paula Kujala⁹⁰, Kirsi Talala⁹¹, Kimmo Taari⁹², Søren Bentzen⁹³, Belynda Hicks⁹⁴, Aurelie Vogt⁹⁴, Amy Hutchinson⁹⁵, Angela Cox⁹⁶, Anne George⁹⁷, Ants Toi⁹⁸, Andrew Evans⁹⁹, Theodorus H. van der Kwast⁹⁹, Takashi Imai¹⁰⁰, Shiro Saito¹⁰¹, Shan-Chao Zhao¹⁰², Guoping Ren¹⁰³, Yangling Zhang¹⁰³, Yongwei Yu¹⁰⁴, Yudong Wu¹⁰⁵, Ji Wu¹⁰⁶, Bo Zhou¹⁰⁷, John Pedersen¹⁰⁸, Ramón Lobato-Busto¹⁰⁹, José Manuel Ruiz-Dominguez¹¹⁰, Lourdes Mengual^{111,112}, Antonio Alcaraz¹¹³, Julio Pow-Sang¹¹⁴, Kathleen Herkommer¹¹⁵, Aleksandrina Vlahova¹¹⁶, Tihomir Dikov¹¹⁶, Svetlana Christova¹¹⁶, Angel Carracedo^{42,117,118}, Brigitte Tretarre¹¹⁹, Xavier Rebillard¹²⁰, Claire Mulot¹²¹, Jan Adolfsson^{122,123}, Par Stattin^{124,125}, Jan-Erik Johansson¹²⁶, Richard M. Martin^{33,127,128}, Ian M. Thompson Jr.¹²⁹, Suzanne Chambers^{130,131}, Joanne Aitken^{130,131}, Lisa Horvath^{132,133}, Anne-Maree Haynes^{86,133}, Wayne Tilley¹³⁴, Gail Risbridger^{135,136}, Markus Aly^{14,137}, Tobias Nordström^{14,138}, Paul Pharoah^{3,139}, Teuvo L.J. Tammela¹⁴⁰, Teemu Murtola^{140,141}, Anssi Auvinen¹⁴², Neil Burnet¹⁴³, Gill Barnett¹⁴³, Gerald Andriole¹⁴⁴, Aleksandra Klim¹⁴⁴, Bettina F. Drake¹⁴⁴, Michael Borre^{27,145}, Sarah Kerns¹⁴⁶, Harry Ostrer¹⁴⁷, Hong-Wei Zhang¹⁴⁸, Guangwen Cao¹⁴⁸, Ji Lin¹⁴⁸, Jin Ling¹⁴⁸, Meiling Li¹⁴⁸, Ninghan Feng¹⁴⁹, Jie Li¹⁵⁰, Weiyang He¹⁵⁰, Xin Guo^{150,151}, Zan Sun¹⁵¹,

Guomin Wang¹⁵², Jianming Guo¹⁵², Melissa C. Southey¹⁵³, Liesel M. FitzGerald^{40,154}, Gemma Marsden^{32,155}, Antonio Gómez-Caamaño¹⁵⁶, Ana Carballo¹⁵⁶, Paula Peleteiro¹⁵⁶, Patricia Calvo¹⁵⁶, Robert Szulkin^{157,158}, Javier Llorca^{45,159}, Trinidad Dierssen-Sotos^{45,159}, Ines Gomez-Acebo^{45,159}, Hui-Yi Lin¹⁶⁰, Elaine A. Ostrander¹⁶¹, Rasmus Bisbjerg¹⁶², Peter Klarskov¹⁶², Martin Andreas Røder¹⁶³, Peter Iversen^{53,163}, Bernd Holleczeck¹⁶⁴, Christa Stegmaier¹⁶⁴, Thomas Schnoeller¹⁶⁵, Philipp Bohnert¹⁶⁵, Esther M. John^{166,167}, Piet Ost¹⁶⁸, Soo-Hwang Teo¹⁶⁹, Marija Gamulin¹⁷⁰, Tomislav Kulis¹⁷¹, Zeljko Kastelan¹⁷¹, Chavdar Slavov¹⁷², Elenko Popov¹⁷², Thomas Van den Broeck^{70,173}, Steven Joniau¹⁷³, Samantha Larkin¹⁷⁴, Jose Esteban Castelao¹⁷⁵, Maria Elena Martinez¹⁷⁶, Ron H.N. van Schaik¹⁷⁷, Jianfeng Xu¹⁷⁸, Sara Lindström¹⁷⁹, Elio Riboli¹⁸⁰, Clare Berry¹⁸⁰, Afshan Siddiq¹⁸¹, Federico Canzian¹⁸², Laurence N. Kolonel¹⁸³, Loic Le Marchand¹⁸³, Matthew Freedman¹⁸⁴, Sylvie Cenee^{75,185} & Marie Sanchez^{75,185}

⁸³Molecular Cancer Epidemiology Laboratory, QIMR Berghofer Institute of Medical Research, Herston, QLD 4006, Australia. ⁸⁴School of Medicine, University of Queensland, Herston, QLD 4006, Australia. ⁸⁵Royal Brisbane and Women's Hospital, Herston, QLD 4029, Australia. ⁸⁶The Kinghorn Cancer Centre (TKCC), Victoria, NSW 2010, Australia. ⁸⁷Prostate Cancer Research Group, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia. ⁸⁸Department of Physiology, Biomedicine Discovery Institute, Cancer Program, Monash University, Melbourne, VIC 3800, Australia. ⁸⁹University of Adelaide, North Terrace, Adelaide, SA 5005, Australia. ⁹⁰Fimlab Laboratories, Tampere University Hospital, FI-33520 Tampere, Finland. ⁹¹Finnish Cancer Registry, FI-00130 Helsinki, Finland. ⁹²Department of Urology, Helsinki University Central Hospital and University of Helsinki, FI-00014 Helsinki, Finland. ⁹³Division of Biostatistics and Bioinformatics, University of Maryland Greenebaum Cancer Center, and Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. ⁹⁴Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and Genetics, FNLRC Leidos Biomedical Research, National Cancer Institute, Frederick, MD 21701, USA. ⁹⁵DNA Extraction and Staging Laboratory (DESL), Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and Genetics, FNLRC Leidos Biomedical Research, National Cancer Institute, Frederick, MD 21701, USA. ⁹⁶Sheffield Institute for Nucleic Acids, University of Sheffield, Sheffield S10 2TN, UK. ⁹⁷Cambridge Cancer Trials Centre, Cambridge Clinical Trials Unit-Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK. ⁹⁸Department of Medical Imaging, University Health Network, Toronto, ON M5G 2C4, Canada. ⁹⁹Department of Pathology, University Health Network, Toronto, ON M5G 2C4, Canada. ¹⁰⁰Advanced Radiation Biology Research Program, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba 263-8555, Japan. ¹⁰¹Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo 152-8902, Japan. ¹⁰²Department of Urology, Nanfang Hospital, Southern Medical University, 510515 Guangzhou, China. ¹⁰³Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, 310009 Hangzhou, China. ¹⁰⁴Department of Pathology, Changhai Hospital, The Second Military Medical University, 200433 Shanghai, China. ¹⁰⁵Department of Urology, First Affiliated Hospital, Medical College, Zhengzhou University, 450003 Zhengzhou, China. ¹⁰⁶Department of Urology, North Sichuan Medical College, 637000 Nanchong, China. ¹⁰⁷Department of Nutrition Science, Shenyang Medical College, 110034 Shenyang, China. ¹⁰⁸Tissupath Pty Ltd., Melbourne, VIC 3122, Australia. ¹⁰⁹Department of Medical Physics, Complejo Hospitalario Universitario de Santiago, SERGAS, 15706 Santiago de Compostela, Spain. ¹¹⁰Urology Department, Hospital Germans Trias i Pujol, 08916 Barcelona, Spain. ¹¹¹Laboratory and Department of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain. ¹¹²Centre de Recerca Biomèdica CELLEX, 08036 Barcelona, Spain. ¹¹³Department and Laboratory of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain. ¹¹⁴Genitourinary Program, Moffitt Cancer Center, Tampa, FL 33612, USA. ¹¹⁵Department of Urology, Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany. ¹¹⁶Department of General and Clinical Pathology, Alexandrovska University Hospital, Medical University, 1431 Sofia, Bulgaria. ¹¹⁷Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 2252 3270, Saudi Arabia. ¹¹⁸Grupo de Medicina Xenómica, CIBERER, CIMUS, Universidad de Santiago de Compostela, Avenida de Barcelona, 15782 Santiago de Compostela, Spain. ¹¹⁹Hérault Cancer Registry, Montpellier cedex 5, 34298 Montpellier, France. ¹²⁰Urology Department, Clinique Beau Soleil, 34070 Montpellier, France. ¹²¹INSERM U1147, 75013 Paris, France. ¹²²Department of Clinical Science, Intervention and Technology, Karolinska Institutet, SE-171 77 Stockholm, Sweden. ¹²³Swedish Agency for Health Technology Assessment and Assessment of Social Services, SE-102 33 Stockholm, Sweden. ¹²⁴Department of Surgical and Perioperative Sciences, Urology and Andrology, Århus University, SE-901 85 Umeå, Sweden. ¹²⁵Department of Surgical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden. ¹²⁶Department of Urology, Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden. ¹²⁷Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol BS8 2BN, UK. ¹²⁸National Institute for Health Research (NIHR) Biomedical Research Centre, University of Bristol, Bristol BS8 1TH, UK. ¹²⁹Department of Urology, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. ¹³⁰Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD 4222, Australia. ¹³¹Cancer Council Queensland, Fortitude Valley, QLD 4006, Australia. ¹³²Chris O'Brien Lifehouse (COBLH), Camperdown, Sydney, NSW 2010, Australia. ¹³³Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. ¹³⁴Dame Roma Mitchell Cancer Research Centre, University of Adelaide, Adelaide, SA 5005, Australia. ¹³⁵Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia. ¹³⁶Prostate Cancer Translational Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. ¹³⁷Department of Molecular Medicine and Surgery, Karolinska Institutet, and Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden. ¹³⁸Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, 182 88 Stockholm, Sweden. ¹³⁹Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK. ¹⁴⁰Department of Urology, Tampere University Hospital, University of Tampere, Kalevantie 4, FI-33014 Tampere, Finland. ¹⁴¹Faculty of Medicine and Life Sciences, University of Tampere, FI-33014 Tampere, Finland. ¹⁴²Department of Epidemiology, School of Health Sciences, University of Tampere, FI-33014 Tampere, Finland. ¹⁴³University of Cambridge Department of Oncology, Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB1 8RN, UK. ¹⁴⁴Washington University School of Medicine, StLouis, MO 63110, USA. ¹⁴⁵Department of Urology, Aarhus University Hospital, 8200 Aarhus N, Denmark. ¹⁴⁶Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14620, USA. ¹⁴⁷Department of Pathology and Pediatrics, Albert Einstein College of Medicine, Bronx, NY 10461, USA. ¹⁴⁸Second Military Medical University, 200433 Shanghai, China. ¹⁴⁹Wuxi Second Hospital, Nanjing Medical University, 214003 Wuxi, Jiangsu, China. ¹⁵⁰Department of Urology, The First Affiliated Hospital, Chongqing Medical University, 200032

Chongqing, China. ¹⁵¹The People's Hospital of Liaoning Province and The People's Hospital of China Medical University, 110001 Shenyang, China. ¹⁵²Department of Urology, Zhongshan Hospital, Fudan University Medical College, 200032 Shanghai, China. ¹⁵³Precision Medicine, School and Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3168, Australia. ¹⁵⁴Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia. ¹⁵⁵Faculty of Medical Science, John Radcliffe Hospital, University of Oxford, Oxford OX1 2JD, UK. ¹⁵⁶Department of Radiation Oncology, Complejo Hospitalario Universitario de Santiago, SERGAS, 15706 Santiago de Compostela, Spain. ¹⁵⁷Division of Family Medicine, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, SE-171 77 Stockholm, Sweden. ¹⁵⁸Scandinavian Development Services, 182 33 Danderyd, Sweden. ¹⁵⁹University of Cantabria-IDIVAL, 39005 Santander, Spain. ¹⁶⁰School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. ¹⁶¹National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA. ¹⁶²Department of Urology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2200 Copenhagen, Denmark. ¹⁶³Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, Copenhagen University Hospital, DK-2730 Herlev, Denmark. ¹⁶⁴Saarland Cancer Registry, 66119 Saarbrücken, Germany. ¹⁶⁵Department of Urology, University Hospital Ulm, 89075 Ulm, Germany. ¹⁶⁶Cancer Prevention Institute of California, Fremont, CA 94538, USA. ¹⁶⁷Department of Health Research and Policy (Epidemiology) and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305-5101, USA. ¹⁶⁸Department of Radiotherapy, Ghent University Hospital, B-9000 Gent, Belgium. ¹⁶⁹Cancer Research Malaysia (CRM), Outpatient Centre, Subang Jaya Medical Centre, 47500 Subang Jaya, Selangor, Malaysia. ¹⁷⁰Urogenital Unit, Division of Medical Oncology, Department of Oncology, University Hospital Centre Zagreb, Šalata 2, 10000 Zagreb, Croatia. ¹⁷¹Department of Urology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Šalata 2, 10000 Zagreb, Croatia. ¹⁷²Department of Urology and Alexandrovska University Hospital, Medical University of Sofia, 1431 Sofia, Bulgaria. ¹⁷³Department of Urology, University Hospitals Leuven, BE-3000 Leuven, Belgium. ¹⁷⁴Southampton General Hospital, The University of Southampton, Southampton SO16 6YD, UK. ¹⁷⁵Genetic Oncology Unit, CHUVI Hospital, Instituto de Investigación Biomédica Galicia Sur (IISGS), Complejo Hospitalario Universitario de Vigo, 36204 Vigo (Pontevedra), Spain. ¹⁷⁶Moores Cancer Center, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA 92093-0012, USA. ¹⁷⁷Department of Clinical Chemistry, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands. ¹⁷⁸Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL 60201, USA. ¹⁷⁹Department of Epidemiology, University of Washington, Seattle, WA 98195, USA. ¹⁸⁰Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London SW7 2AZ, UK. ¹⁸¹Genomics England, Queen Mary University of London, Dawson Hall, Charterhouse Square, London EC1M 6BQ, UK. ¹⁸²Genomic Epidemiology Group, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany. ¹⁸³Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA. ¹⁸⁴Dana-Farber Cancer Institute, Boston, MA 02215, USA. ¹⁸⁵Paris-Sud University, UMRS 1018, Cedex 94807 Villejuif, France. Deceased: Brian E. Henderson.